POU5FI, encoding a key regulator of stem cell pluripotency, is fused to EWSRI in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands

Journal of Pathology

Volumn 215, Issue 1, 2008, Pages 78-86

  Moller E ^a   Stenman, G ^b   Mandahl, N ^a   Hamberg, H ^c   Molne L ^b   Van Den Oord, J J ^d   Brosjo O ^e   Mertens, F ^a   Panagopoulos, I ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dual luciferase assay; EWSR1; Fusion gene; Hidradenoma; Mucoepidermoid carcinoma; OCT 3 4; POU5F1; Transcriptional activation; Translocation

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN EWSR1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX; CALMODULIN BINDING PROTEIN; EWSR1 PROTEIN, HUMAN; ONCOPROTEIN; POU5F1 PROTEIN, HUMAN; RNA BINDING PROTEIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CHIMERA; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HIDRADENOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND CARCINOMA; SKIN TUMOR; TRANSCRIPTION INITIATION; WILD TYPE; CASE REPORT; CHROMOSOME 22; CHROMOSOME 6; CHROMOSOME MAP; GENE TRANSLOCATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PREGNANCY; SALIVARY GLAND;

ADENOMA, SWEAT GLAND; ADULT; CALMODULIN-BINDING PROTEINS; CARCINOMA, MUCOEPIDERMOID; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OCTAMER TRANSCRIPTION FACTOR-3; ONCOGENE PROTEINS, FUSION; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; SALIVARY GLANDS; SKIN NEOPLASMS; TRANSFECTION; TRANSLOCATION, GENETIC;

EID: 42949150065     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2327     Document Type: Article

References (47)

1. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-165.
2. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007;7:233-245.
3. Riggi N, Cironi L, Suva ML, Stamenkovic I. Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol 2007;213:4-20.
4. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14:3230-3241.
5. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS-FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13:7393-7398.
6. Rossow KL, Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 2001;61:2690-2695.
7. Yamaguchi S, Yamazaki Y, Ishikawa Y, Kawaguchi N, Mukai H, NakamuraT. EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12). Genes Chromosomes Cancer 2005;43:217-222.
8. Herr W, Cleary MA. The POU domain: versatility in transcriptional regulation by a flexible two-in-one DNA-binding domain. Genes Dev 1995;9:1679-1693.
9. Klemm JD, Rould MA, Aurora R, Herr W, Pabo CO. Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell 1994;77:21-32.
10. Pesce M, Schöler HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells 2001;19:271-278.
11. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000;24:372-376.
12. Goto T, Adjaye J, Rodeck CH, Monk M. Identification of genes expressed in human primordial germ cells at the time of entry of the female germ line into meiosis. Mol Hum Reprod 1999;5:851-860.
13. Hansis C, Grifo JA, Krey LC. Oct-4 expression in inner cell mass and trophectoderm of human blastocysts. Mol Hum Reprod 2000;6:999- 1004.
14. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000;18:399-404.
15. Behboudi A, Enlund F, Winnes M, Andren Y, Nordkvist A, Leivo I, et al. Molecular classification of mucoepidermoid carcinomas - prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 2006;45:470-481.
16. Winnes M, Mölne L, Suurküla M, Andrén Y, Persson F, Enlund F, et al. Frequent fusion of the CRTC1 and MAML2 genes in clear cell variants of cutaneous hidradenomas. Genes Chromosomes Cancer 2007;46:559-563.
17. Behboudi A, Winnes M, Gorunova L, van den Oord JJ, Mertens F, Enlund F, et al. Clear cell hidradenoma of the skin - a third tumor type with a t(11;19)-associated TORC1-MAML2 gene fusion. Genes Chromosomes Cancer 2005;43:202-205.
18. Dahlén A, Debiec-Rychter M, Pedeutour F, Domanski HA, Höglund M, Bauer HC, et al. Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer 2003;103:616- 623.
19. Panagopoulos I, Mertens F, Domanski HA, Isaksson M, Brosjö O, Gustafson P, et al. No EWS/FLI1 fusion transcripts in giant-cell tumors of bone. Int J Cancer 2001;93:769-772.
20. Panagopoulos I, Möller E, Dahlén A, Isaksson M, Mandahl N, Vlamis-Gardikas A, et al. Characterization of the native CREB3L2 transcription factor and the FUS/CREB3L2 chimera. Genes Chromosomes Cancer 2007;46:181-191.
21. Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 2005;25:6031-6046.
22. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 2005;280:24731-24737.
23. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003;33:208-213.
24. McNiff J, McCalmont T, Requena L, Sangueza O, Vassallo C, Rosso R, et al. Benign tumours with apocrine and eccrine differentiation. In World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours, LeBoit P, Burg G, Weedon D, Sarasin A (eds). IARC Press: Lyon, 2006; 139-151.
25. Requena L, Kutzner H, Hurt M, Santa Cruz D, Mehregan D, Mengesha Y, et al. Malignant tumours with apocrine and eccrine differentiation. In World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours, LeBoit P, Burg G, Weedon D, Sarasin A (eds). IARC Press: Lyon, 2006; 125-138.
26. Mambo NC. The significance of atypical nuclear changes in benign eccrine acrospiromas: a clinical and pathological study of 18 cases. J Cutan Pathol 1984;11:35-44.
27. Goode R, El-Naggar A. Mucoepidermoid carcinoma. In World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson J, Reichart P, Sidransky D (eds). IARC Press: Lyon, 2005; 219-220.
28. Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M, et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res 2006;12:3902-3907.
29. Jin Y, Jin C, Mertens F, Persson B, Jonsson N. Characterization of a malignant eccrine poroma by cytogenetic and fluorescence in situ hybridization techniques. Cancer Genet Cytogenet 1998;102:100-103.
30. Liu J, Nau MM, Yeh JC, Allegra CJ, Chu E, Wright JJ. Molecular heterogeneity and function of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors. Clin Cancer Res 2000;6:3522-3529.
31. Peter M, Mugneret F, Aurias A, Thomas G, Magdelenat H, Delattre O. An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumor. Int J Cancer 1996;67:339-342.
32. Brown AD, Lopez-Terrada D, Denny C, Lee KA. Promoters containing ATF-binding sites are deregulated in cells that express the EWS/ATF1 oncogene. Oncogene 1995;10:1749-1756.
33. Lee J, Kim JY, Kang IY, Kim HK, Han YM, Kim J. The EWS-Oct-4 fusion gene encodes a transforming gene. Biochem J 2007;406:519- 526.
34. Lee J, Rhee BK, Bae GY, Han YM, Kim J. Stimulation of Oct-4 activity by Ewing's sarcoma protein. Stem Cells 2005;23:738-751.
35. Lee J, Kim HK, Rho JY, Han YM, Kim J. The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem 2006;281:33554-33565.
36. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003;4:361-370.
37. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-2250.
38. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007;120:1598-1602.
39. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005;121:465-477.
40. de Jong J, Looijenga LH. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog 2006;12:171-203.
41. Grinnell KL, Yang B, Eckert RL, Bickenbach JR. Dedifferentiation of mouse interfollicular keratinocytes by the embryonic transcription factor Oct-4. J Invest Dermatol 2007;127:372-380.
42. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007;25:1177-1181.
43. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES cell-like state. Nature 2007;448:318-324.
44. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
45. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-1920.
46. Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, et al. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB-regulated genes. Cancer Res 2005;65:7137-7144.
47. Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, et al. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J 2005;24:2391-2402.